GlassScriptPhysician profile
Christopher Conrad Nagle
NPI 1356528111
$7,582.67
in general payments reported to CMS, 2019-2025
39 companies · $18.60 in 2025
The $18.60 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $815 · 2020: $775 · 2021: $2,386 · 2022: $1,541 · 2023: $1,142 · 2024: $905 · 2025: $18.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,065.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,380.59 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $1,278.62 | 2021 | |
| Lilly USA, LLC | $776.38 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $674.58 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $514.69 | 2019-2024 | Farxiga |
| Amgen INC. | $441.70 | 2019-2024 | Otezla, Repatha, Prolia |
| Pfizer INC. | $280.92 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.57 | 2019-2024 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $165.25 | 2020-2023 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $151.95 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $149.82 | 2019-2023 | Trintellix |
| Amarin Pharma, INC. | $145.98 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $125.54 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.31 | 2019-2022 | |
| Welch Allyn | $120.72 | 2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Nagle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.